Issue navigation
Volume 69, Issue Supplement_7, 1 December 2019
The Development of Cefiderocol (S-649266), A Novel Siderophore Cephalosporin, in the Era of Multidrug-Resistant Gram-Negative Bacterial Infection
Supplement Articles
Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
Clinical Infectious Diseases, Volume 69, Issue Supplement_7, 1 December 2019, Pages S519–S520, https://doi.org/10.1093/cid/ciz823
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
Clinical Infectious Diseases, Volume 69, Issue Supplement_7, 1 December 2019, Pages S521–S528, https://doi.org/10.1093/cid/ciz824
The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics
Clinical Infectious Diseases, Volume 69, Issue Supplement_7, 1 December 2019, Pages S529–S537, https://doi.org/10.1093/cid/ciz825
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Clinical Infectious Diseases, Volume 69, Issue Supplement_7, 1 December 2019, Pages S538–S543, https://doi.org/10.1093/cid/ciz826
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
Clinical Infectious Diseases, Volume 69, Issue Supplement_7, 1 December 2019, Pages S544–S551, https://doi.org/10.1093/cid/ciz827
Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
Clinical Infectious Diseases, Volume 69, Issue Supplement_7, 1 December 2019, Pages S552–S558, https://doi.org/10.1093/cid/ciz828
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
Clinical Infectious Diseases, Volume 69, Issue Supplement_7, 1 December 2019, Pages S559–S564, https://doi.org/10.1093/cid/ciz829
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Clinical Infectious Diseases, Volume 69, Issue Supplement_7, 1 December 2019, Pages S565–S575, https://doi.org/10.1093/cid/ciz830
